Bio­gen sues com­pa­ny al­leged­ly sell­ing ad­u­canum­ab copy­cat; J&J takes on No­var­tis' MS fran­chise

→ Bio­gen is tak­ing Cre­ative Bi­o­labs to court, claim­ing the com­pa­ny is sell­ing an unau­tho­rized ver­sion of its Alzheimer’s drug ad­u­canum­ab, ac­cord­ing to Bloomberg. The con­tro­ver­sial drug has aroused a tem­pest of dis­cus­sion around the case Bio­gen has been mak­ing for an ap­proval. Right now, though, it has yet to be sub­mit­ted and the big biotech is in­tent on keep­ing sole rights to the ther­a­py in its hands.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER